Prolacta Formula Fortifier Starts Trial For Newborns With Rare Heart Condition
This article was originally published in The Rose Sheet
Prolacta Bioscience developed human milk-based formula fortifier for full-term infants born with conditions that make them vulnerable to nutrition deficiencies. Pending results from research at 12 US hospitals, the product would roll out commercially in 2018.
You may also be interested in...
Beginning in July 2014 manufacturers must test infant formulas for salmonella and cronobacter before distribution, according to an IFR and guidances FDA released Feb. 6. The rule also requires firms to prove formula meets quality standards including providing all necessary nutrients and appropriate levels of protein.
USANA reports some Active Nutrition supplement line extensions s could be delayed to early 2022 due to pandemic-related disruptions, but it reaffirms its full-year sales and diluted EPS projections.
Using web app for self-selection was successful with more than 95% concordance for the primary endpoint comparing results obtained by participants and independent clinical assessments, say researchers led by cardiologist and consumer health innovation advocate Steven Nissen.